Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on February 12, 2008
JNCI Journal of the National Cancer Institute 2008 100(4):234-236; doi:10.1093/jnci/djn031
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
100/4/234    most recent
djn031v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by McNeil, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McNeil, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2008.

NEWS

Quality of Life Researchers Have New Tool and New Focus on Measurement

Caroline McNeil

The first 150 words of the full text of this article appear below.

More attention to quality of life (QOL) has been on the agenda of oncology groups for at least three decades. Most researchers agree that measuring QOL endpoints, such as pain or physical function, is important because they can affect adherence to treatment and outcome. QOL also matters because of increasing survival times among cancer patients.

"If you're looking at 5- to 10-year survival times, it makes sense to be interested in quality of life," said Lori Minasian, M.D., who leads the National Cancer Institute Community Oncology and Preventive Trials Research Group.


Figure Removed (Available Only in the Full Text)
View larger version (132K):



  		Lori Minasian, M.D.

 
But using QOL endpoints in clinical trials has been challenging. Problems include the extra burden on patients and staff and the related issue of missing data—many people simply do not fill out QOL surveys.

But the major challenge has been the difficulty of measuring these patient-reported outcomes (PROs)—the umbrella term now used almost interchangeably with . . . [Full Text of this Article]

Evidence Base

Years of Discussion

FDA's New Criteria Stress Single Measures, Documentation


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?